AFP, a hepatoblast marker, is used clinically as a biomarker for HCC, although an association with fibrosis has previously been observed in chronic HBV[29], and reduced AFP levels were associated with fibrosis regression following interferon therapy in patients with chronic HCV[30]. This evidence concerns the gene AFP and hepatocellular carcinoma.